bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 866: The epithelial-to-mesenchymal transition regulates E-selectin ligand activities of breast cancer cells
Authors: Carlson Grady E. , Ostermann Alexander O. , Shirure Venktesh S. , Benencia Fabian , Burdick Monica M. 
Published: July 2017

Abstract
The epithelial-to-mesenchymal transition (EMT) leads to specific stem-like and invasive properties in breast cancer cells. However, it remains unclear whether the EMT modifies sialofucosylated ligands that circulating tumor cells use to attach and adhere to vascular endothelial E-selectin during metastasis. To address this issue, immunohistochemistry and E-selectin microsphere dynamic adhesion assays were initially used to assay 110 cases of breast cancer for EMT biomarkers and E-selectin ligand activity. The expression of E-cadherin, but not N-cadherin or vimentin, directly correlated with E-selectin ligand activity. Thus, it was hypothesized that the EMT, and in turn the mesenchymal-to-epithelial transition (MET), regulate expression of functional E-selectin ligands in breast cancer cells. The ectopic expression or shRNA knockdown of transcription factors (i.e., Snail and Twist) in target cell lines were used to induce EMT or MET, respectively. Shear flow adhesion assays and flow cytometry demonstrated that cells with epithelial phenotypes had greater E-selectin ligand activities and greater expression of sialofucosylated carbohydrates compared to cells with mesenchymal phenotypes. Moreover, glycoprotein E-selectin ligand activities of breast cancer cells were more affected by the EMT compared to glycolipid E-selectin ligand activities. Assessing expression of α1,3- and α1,4- fucosyltransferases (FUT) at the RNA level using qRT-PCR revealed that FUT3 and FUT6 gene expression were decreased via the EMT, corresponding to the lowered E-selectin ligand activities observed in mesenchymal phenotype cells. Altogether, the results of this investigation demonstrate that the EMT, as well as the MET, mechanistically regulate the expression of functional E-selectin ligands expressed by breast cancer cells.
Citation Format: Grady E. Carlson, Alexander O. Ostermann, Venktesh S. Shirure, Fabian Benencia, Monica M. Burdick. The epithelial-to-mesenchymal transition regulates E-selectin ligand activities of breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 866. doi:10.1158/1538-7445.AM2017-866
Abstract 88: The role of RBPMS in cisplatin resistant ovarian cancer
Authors: Báez-Vega Perla M. , Valiyeva Fatma , Santiago Ginette , Vivas-Mejia Pablo 
Published: July 2017

Abstract
Epithelial ovarian cancer is the fifth leading cause of cancer-associated deaths among women in the United States. High-grade serous ovarian cancer (HGSOC) is the most common type of epithelial ovarian cancer and accounts for 70-80% of ovarian cancer patient deaths. RNA-Binding Protein With Multiple Splicing (RBPMS) is a member of a family of proteins that bind to the nascent RNA transcripts and regulate their processing, including the pre-mRNA splicing and the transport, localization, and stability of the RNA molecules. However, little is known about the biological function of RBPMS family in ovarian cancer. We hypothesized that decreasing the expression of RBPMS in high-grade serous ovarian cancer increases ovarian cancer progression and platinum-based drug resistance. Quantitative real-time PCR (qPCR) and Western blot (WB) analysis were conducted to determine the basal mRNA and protein expression of RBPMS in ovarian cancer cells. The invasion ability of the ovarian cancer cells after targeting RBPMS with silencing RNA (siRNA) was determined by invasion assays. The proliferation rate of the ovarian cancer cells overexpressing RBPMS was determine by colony formation assay. RBPMS is highly expressed in A2780 cells when compared to the cisplatin resistance ovarian cancer cells and HGSOC cancer cells. Targeting RBPMS increased the invasion ability of the A2780 cells. Cisplatin resistant, A2780CP20 cells overexpressing RBPMS showed a decreased in cell proliferation when compared to the A2780CP20 empty vector clones. We described here for the first time the mRNA and protein expression profile of RBPMS in HGSOC and epithelial ovarian cancer cells. These studies will help to better understand the role of RBPMS in ovarian cancer and may support the use of RBPMS as an adjuvant treatment to overcome the platinum-based chemotherapy resistance characteristic of the high-grade serous ovarian cancer.
Note: This abstract was not presented at the meeting.
Citation Format: Perla M. Báez-Vega, Fatma Valiyeva, Ginette Santiago, Pablo Vivas-Mejia. The role of RBPMS in cisplatin resistant ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 88. doi:10.1158/1538-7445.AM2017-88
Abstract 886: An integrative platform for three-dimensional quantitative analysis of spatially heterogeneous metastasis landscapes
Authors: Guldner Ian H. , Yang Lin , Liu Fang , Chen Danny Z. , Zhang Siyuan 
Published: July 2017

Abstract
Metastatic microenvironments are spatially and compositionally heterogeneous. This seemingly stochastic heterogeneity provides researchers great challenges in elucidating factors that determine metastatic outgrowth. Herein, we develop and implement an integrative platform that will enable researchers to obtain novel insights from intricate metastatic landscapes. Our two-segment platform begins with whole tissue clearing, staining, and imaging to globally delineate metastatic landscape heterogeneity with spatial and molecular resolution. The second segment of our platform applies our custom-developed SMART 3D (Spatial filtering-based background removal and Multi-chAnnel forest classifiers-based 3D ReconsTruction), a multi-faceted image analysis pipeline, permitting quantitative interrogation of functional implications of heterogeneous metastatic landscape constituents, from subcellular features to multicellular structures, within our large three-dimensional (3D) image datasets. Coupling whole tissue imaging of brain metastasis animal models with SMART 3D, we demonstrate the capability of our integrative pipeline to reveal and quantify volumetric and spatial aspects of brain metastasis landscapes, including diverse tumor morphology, heterogeneous proliferative indices, metastasis-associated astrogliosis, and vasculature spatial distribution. Collectively, our study demonstrates the utility of our novel integrative platform to reveal and quantify the global spatial and volumetric characteristics of the 3D metastatic landscape with unparalleled accuracy, opening new opportunities for unbiased investigation of novel biological phenomena in situ.
Citation Format: Ian H. Guldner, Lin Yang, Fang Liu, Danny Z. Chen, Siyuan Zhang. An integrative platform for three-dimensional quantitative analysis of spatially heterogeneous metastasis landscapes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 886. doi:10.1158/1538-7445.AM2017-886
Abstract 894: Heparanase-induced shedding of syndecan-1 promotes cancer cell invasion : prevention by inhibitory synstatin peptide
Authors: Jung Oisun , Rapraeger Alan 
Published: July 2017

Abstract
Syndecan-1 (Sdc1, CD138) is highly expressed in multiple myeloma (MM). Heparanase (HPSE), an enzyme that cleaves heparan sulfate (HS) chains on Sdc1, induces shedding of the Sdc1 ectodomain; this is associated with poor prognosis in this disease. However, the link between Sdc1 shedding and poor prognosis remains unclear. We now show that HPSE-induced shed Sdc1 (sSdc1) engages α4β1 integrin (VLA-4) and vascular endothelial cell growth factor receptor-2 (VEGFR2) to form a ternary receptor complex on the cell surface. This coupling of VEGFR2 to clusters of VLA-4 via sSdc1 leads to autoactivation of VEGFR2 and the subsequent activation of protein kinase A (PKA) bound to the VEGFR2 cytoplasmic domain. PKA activation proceeds via VEGFR2-mediated stimulation of the G-protein coupled cytokine receptor CXCR4 and the subsequent generation of cAMP by its activation of adenylate cyclase 7. This mechanism is prevented by SSTNVEGFR2, a peptide that competes for the VEGFR2 docking site in the Sdc1 ectodomain, thereby disrupting VEGFR2 binding to sSdc1. VLA-4 has been shown to mediate the polarized invasion of a variety of cells due to α4 integrin phosphorylation on Ser988 by PKA, followed by Rac GTPase activation, a process that is restricted to the leading edge of the cell. But how this is confined at the leading edge is wholly unknown. We find that HPSE-mediated shedding of Sdc1 promotes an invasive phenotype by re-localizing VLA-4 and VEGFR2 to the leading edge of migrating myeloma cells as well as human T-acute lymphoblastic leukemia, melanoma, and endothelial cells where VEGFR2-dependent PKA activation causes α4 integrin phosphorylation. These results reveal a novel mechanism in which the expression of HPSE, acting by causing Sdc1 shedding, potentially regulates angiogenesis and the extravasation and invasion of cancer cells and identifies SSTNVEGFR2 as a promising cancer therapeutic.
Citation Format: Oisun Jung, Alan Rapraeger. Heparanase-induced shedding of syndecan-1 promotes cancer cell invasion : prevention by inhibitory synstatin peptide [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 894. doi:10.1158/1538-7445.AM2017-894
Abstract 896: Long term exposure to Oroxylin A inhibits cell migration via suppressing CCL2 in oral squamous cell carcinoma cells
Authors: Tung Jiun-Jia , Lee Tony Jer-Fu , Ku Wei-Ting , Lai Kuo-Chu 
Published: July 2017

Abstract
Oral squamous cell carcinoma (OSCC) is the sixth most common cancer in the world. Like other cancers, the major causes of OSCC-related death are cervical node and distant metastasis. Therefore, it is a critical need to identify new potential therapeutic agents against OSCC migration, invasion, and metastasis. Oroxylin A, a main bioactive flavonoids extracted from Scutellaria radix, has been reported to inhibit migration in breast and non-small-cell lung cancer. In this study, we explored the anti-migration effects of oroxylin A on OSCC cells and investigated its underlying mechanisms. A 24-hour exposure (short-term) of OSCC cells to oroxylin A at noncytotoxic concentrations (5-20 μM) significantly suppressed cell migration using the wound healing assay. Furthermore, a 30-days exposure (long-term) to oroxylin A (20 μM), which still had no cytotoxic effect on OSCC cells, but significantly suppressed more cell migration than that of short-term oroxylin A exposed OSCC cells. To uncover the molecular mechanisms involved in the inhibitory effect of oroxylin A on OSCC migration, cDNA microarray technique and Ingenuity software were used. There were 468 differentially expressed genes, including 112 upregulated and 356 downregulated genes identified in long-term oroxylin A exposed cells compared to untreated OSCC cells. Among them, 77 genes have been reported to be associated with cancer cell migration. Consistent with results from cDNA microarray, we revealed that the expressions of several cell migration-related genes, such as CCL2, S100A9, LCN2, and THBS1 were significantly decreased in long-term oroxylin A exposed OSCC cells using QPCR assay. Western blotting and ELISA results also demonstrated that CCL2 expressions at mRNA and protein levels were significantly decreased in long-term oroxylin A exposed OSCC cells compared to untreated OSCC cells. In the meantime, the expressions of downstream targets of CCL2, including p-ERK, NFκB, MMP2, and MMP9 were also decreased in long-term oroxylin A exposed OSCC cells. These results suggest that long-term oroxylin A treatment inhibits migration may via suppressing CCL2 in OSCC cells.
Citation Format: Jiun-Jia Tung, Tony Jer-Fu Lee, Wei-Ting Ku, Kuo-Chu Lai. Long term exposure to Oroxylin A inhibits cell migration via suppressing CCL2 in oral squamous cell carcinoma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 896. doi:10.1158/1538-7445.AM2017-896
Abstract 902: Cancer-stem-cell (CSC) marker, DCLK1-S, enhances invasive potential of cancer cells by phosphorylating/activating NFATc2: role of COL3A1 and SPARC in mediating metastatic effects of DCLK1-S/NFATc2
Authors: Connell Malaney O. , Sarkar Shubhashish , Spratt Heidi , Widen Steven , Wood Thomas G. , Singh Pomila 
Published: July 2017

Abstract
DCLK1 expression is critically required for colon carcinogenesis in mice, and for maintaining tumorogenic potential of human colon cancer cells (hCCCs) (Singh et al, 2016). Down-regulation of DCLK1, combined with chemoprevention, eliminates CSCs, and avoids colon cancer relapse (Kantara et al, 2014). We recently discovered that long (L) and Short (S) isoforms of DCLK1 (DCLK1-L/DCLK1-S) are transcribed by two separate promoters (5’(α)/IntronV(β)) in the hDCLK1-gene (O’Connell et al, 2015). During adenoma-carcinoma sequence of colon-tumorigeneses, L-isoform becomes silenced by DNA-methylation while S-isoform gets upregulated by many fold (O’Connell et al, 2015). S-isoform specifically imparts invasive potential to cancer cells, unlike L-isoform (Singh et al, 2016); others have similarly reported metastatic potential of DCLK1 expressing cancer cells (Ito et al, 2016). Thus the goal of our studies was to evaluate molecular/genetic pathways mediating invasive effects of DCLK1-S in cancer cells. Isogenic clones of HCT116-cells, wild-type or down-regulated for DCLK1-S (HCT-C/HCT-D), were subjected to next generation sequencing and pathways analysis. SPARC and COL3A1 emerged as two candidate genes/proteins, which were decreased/increased by several fold in response to loss/overexpression of DCLK1-S, respectively. We present data confirming a critical role of COL3A1 and SPARC in mediating metastatic effects of DCLK1-S expression in hCCCs. We additionally discovered that DCLK1-S functions as a specific kinase for the transcriptional factor, NFATc2, and phosphorylates 53SPPS56 motif of NFATc2, resulting in activation of NFATc2 and increased expression of COL3A1. Conclusions. Our novel findings, suggest for the first time, that DCLK1-S expression by colonic tumors in humans, mediates invasive potential of colon cancer cells by phosphorylation/activation of NFATc2, resulting in up-regulation of COL3A1/SPARC; the latter proteins re-model extracellular matrix, assisting unhindered invasion of colon cancer cells.
Note: This abstract was not presented at the meeting.
Citation Format: Malaney O. Connell, Shubhashish Sarkar, Heidi Spratt, Steven Widen, Thomas G. Wood, Pomila Singh. Cancer-stem-cell (CSC) marker, DCLK1-S, enhances invasive potential of cancer cells by phosphorylating/activating NFATc2: role of COL3A1 and SPARC in mediating metastatic effects of DCLK1-S/NFATc2 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 902. doi:10.1158/1538-7445.AM2017-902
Abstract 908: A role for MST4 in organelle organization and breast cancer cell vascular invasion
Authors: Berens Eric B. , Gilardi Mara , Moretti Matteo , Riegel Anna T. , Wellstein Anton 
Published: July 2017

Abstract
There exist 5 Mammalian Sterile20-like (MST) kinases that are broadly distributed into two subgroups. While MST1 and MST2 have established roles in the canonical Hippo signaling pathway, MST3, MST4, and YSK1 are known to regulate the actin cytoskeleton and cell polarity. Here we clarify distinct roles for MST3 vs. MST4 in breast cancer cell lines. Stable knockdown of MST4, but not MST3, enhances the ability of breast cancer cells to disrupt an endothelial monolayer as well as invade from an endothelial network formed within a microfluidic device. In addition, depletion of MST4 in MDA-MB-231 cells alters their morphology, induces abnormalities in nuclear structure, and affects the organization of cellular organelles like the Golgi apparatus. We conclude that, despite their relative homology, MST4 versus MST3 uniquely impacts the intracellular organelle status and vascular invasive behavior of breast cancer cells.
Citation Format: Eric B. Berens, Mara Gilardi, Matteo Moretti, Anna T. Riegel, Anton Wellstein. A role for MST4 in organelle organization and breast cancer cell vascular invasion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 908. doi:10.1158/1538-7445.AM2017-908
Abstract 910: Phloridzin docosahexaenoate (PZ-DHA) inhibits breast cancer cell invasion and angiogenesis
Authors: Fernando Wasundara , MacLean Emma , Coyle Krysta , Marcato Paola , Hoskin David W. , Rupasinghe H. P. Vasantha 
Published: July 2017

Abstract
In our previous studies, we showed the selective cytotoxicity, in vitro anti-proliferative and anti-metastatic activities of phloridzin docosahexaenoate (PZ-DHA). PZ-DHA combines phloridzin (PZ), a dihydrochalcone found in apple peels, and docosahexaenoic acid (DHA), an ω-3 fatty acid found in fish oil, through an acylation reaction. Significant suppression of tumor growth resulted from the intratumoral administration of PZ-DHA to non-obese diabetic severe combined immunodeficient (NOD-SCID) female mice xenografted with MDA-MB-231 breast cancer cells. Examination of haematoxylin and eosin-stained tumor sections confirmed that PZ-DHA caused tumor cell death. PZ-DHA also suppressed the invasion of MDA-MB-231 cells through membranes coated with extra cellular matrix proteins, fibronectin and gelatin, in a Boyden chamber assay. The effect of PZ-DHA on the mRNA transcription of the gelatinase, matrix metalloproteinase-2 (MMP-2,) was measured in RT-qPCR analysis, which showed that MMP-2 mRNA expression was inhibited at 12 h and 24 h following PZ-DHA treatments. Furthermore, suppression of MMP-2 protein expression was shown by western blot analysis of cell lysates of PZ-DHA-treated MDA-MB-231 cells. Intraperitoneal administration of PZ-DHA suppressed the growth of primary tumors and metastasis of 4T1 and green fluorescence protein (GFP)-tagged-MDA-MB-231 cells to lungs of BALB/c and NOD-SCID female mice, respectively. Anti-angiogenic activity of PZ-DHA was investigated using human umbilical vein endothelial cells (HUVECs). PZ-DHA suppressed the metabolic activity of HUVECs in MTS assays and the cell death was confirmed using flow cytometric analysis of 7-AAD and Annexin-V-FLUOS/propidium iodide-stained HUVECs. Anti-proliferative activity of PZ-DHA was shown using Oregon Green 488 stained-HUVECs by flow cytometry. PZ-DHA treatment arrested the HUVEC cell cycle at S-phase. PZ-DHA also suppressed the migration of HUVECs in a gap closure assay and inhibited HUVEC tubule formation on a matrigel matrix. For comparison purposes, PZ and DHA were included in all experiments, but in all cases were less effective than PZ-DHA. Taken together, these findings reveal the potential of PZ-DHA to inhibit triple-negative breast cancer progression. We are currently working on identifying potential phase I and II metabolites of PZ-DHA and understanding its pharmacokinetic parameters.
Citation Format: Wasundara Fernando, Emma MacLean, Krysta Coyle, Paola Marcato, David W. Hoskin, H. P. Vasantha Rupasinghe. Phloridzin docosahexaenoate (PZ-DHA) inhibits breast cancer cell invasion and angiogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 910. doi:10.1158/1538-7445.AM2017-910
Abstract 914: Age-associated neoplastic transformation of mammary stem cells
Authors: Gu Xiang , Bouamar Hakim , Pressley Kyle , Sun LuZhe 
Published: July 2017

Abstract
Incidence rate of breast cancer increases significantly with age. However, the mechanism of age-associated mammary tumorigenesis is unknown. Although mammary stem/progenitor cells have been proposed as the cells of origin for breast cancer, the mechanism remains largely elusive. Previously we discovered that in the old (28 to 30 month-old) mouse mammary gland, the luminal cells in the hyperplastic lesions elevated expression of CD49f, which is a basal cell marker. This led to an increased percentage of mammary stem cells (MaSCs) marked by CD49fhi in the old in comparison to the young (3 to 6 month-old). Similarly, old (&gt;60 yr) human mammary ducts in the adjacent normal tissues from patients with breast cancer showed more hyperplastic lesions and CD49fhi luminal cells than young (&lt;40 yr) tissues. Regenerated mammary glands by the old CD49fhi MaSCs through in vivo transplantation in cleared mammary fat pads showed more hyperplastic and dysplastic lesions than those regenerated by the young CD49fhi MaSCs, suggesting the old CD49fhi MaSCs contain transformed MaSCs. Moreover, gene set enrichment analysis of whole genome transcriptome data showed that they also have elevated expression of luminal cell specific genes and reduced expression of basal cell specific genes. Through large scale screening with flow cytometry guided by bioinformatics analysis, we found that Lin- CD24med CD49fhi CD13+ CD73- mammary epithelial cells had increased number of MaSCs. By comparing young (3 to 6 months old) and old Balb/C mice, we found that the frequency of this specific MaSCs was significantly increased by four folds in old mammary epithelial cells (young: 4%, old: 16%). In contrast, relative percentage of Lin- CD24med CD49fhi CD13- CD73+ cells significantly decreased (young: 46%, old: 16%) during aging while the CD13 and CD73 double positive or double negative subpopulations remained unchanged. CD13+ CD73- cells generated significantly many more mammospheres (around 40 spheres per 1,000 cells) in suspension culture than other three types of cells (around 2 spheres per 1,000 cells). However, there was no significant difference between the young and old in terms of sphere formation efficiency for any of the four subpopulations marked by CD13 and CD73. We are studying whether anyone of these four subpopulation from CD49fhi old cells will generate more hyperplastic and dysplastic lesions in regenerated glands than the other subpopulations as well as than the corresponding young subpopulation. Our study show that CD13 and CD73 may be the markers for the identification of tumor-initiating MaSCs.
Citation Format: Xiang Gu, Hakim Bouamar, Kyle Pressley, LuZhe Sun. Age-associated neoplastic transformation of mammary stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 914. doi:10.1158/1538-7445.AM2017-914